Axonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies
| dc.contributor.author | Inmongkol C. | |
| dc.contributor.author | Vorasan N. | |
| dc.contributor.author | Limpaninlachat S. | |
| dc.contributor.author | Sereephaowong N. | |
| dc.contributor.author | Kulsirichawaroj P. | |
| dc.contributor.author | Sanmaneechai O. | |
| dc.contributor.author | Burns J. | |
| dc.contributor.correspondence | Inmongkol C. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2026-06-09T18:15:27Z | |
| dc.date.available | 2026-06-09T18:15:27Z | |
| dc.date.issued | 2026-12-01 | |
| dc.description.abstract | Background: Charcot–Marie–Tooth disease and related neuropathies (CMTR) are heterogeneous inherited neuropathies with variable progression, yet data on pediatric disease progression by neurophysiological subtype are limited. We evaluated 1-year clinical and functional changes in children with CMTR and compared axonal versus demyelinating trajectories. Methods: We conducted a prospective cohort study of 20 Thai children with CMTR who were aged 3–20 years. Participants were assessed at baseline and after 1 year using the Rasch-modified Charcot–Marie–Tooth Examination Score (CMTES-R), Charcot–Marie–Tooth Pediatric Scale (CMTPedS), manual muscle testing (MMT), Foot Posture Index, and muscle length testing. Within-subject changes in clinical outcomes over time were assessed using appropriate paired statistical tests. Results: Thirteen patients had axonal forms and seven had demyelinating forms; the patients’ mean age was 13.0 ± 4.9 years. The axonal variants involved MFN2 (n = 3), GDAP1 (n = 2), and GAN, GJB1, IGHMBP2, KIF1A, PRDM12 (n = 1 each); 3 axonal variants were genetically undiagnosed. The demyelinating variants comprised MPZ (n = 2), PMP22 duplication (n = 2), EGR2 (n = 1), NEFL (n = 1), and PMP22 deletion (n = 1). At both time points, 85% of the patients were ambulatory, 15% used a wheelchair, and 65% used an ankle-foot orthosis. CMTPedS increased by 1.0 ± 3.4 points over 1 year (p = 0.271), with a larger change in axonal versus demyelinating cases (+ 1.1 ± 3.2 vs. + 0.7 ± 4.0). CMTES-R changed minimally (median + 0.5), and MMT showed stable strength. Conclusion: The clinical progression in pediatric CMTR was heterogeneous and differed by neurophysiological subtype, with more pronounced 1-year functional decline in axonal disease. These findings support vigilant longitudinal monitoring of pediatric CMTR, particularly where genetic testing access is limited. | |
| dc.identifier.citation | BMC Neurology Vol.26 No.1 (2026) | |
| dc.identifier.doi | 10.1186/s12883-026-04888-4 | |
| dc.identifier.eissn | 14712377 | |
| dc.identifier.pmid | 42010503 | |
| dc.identifier.scopus | 2-s2.0-105040748711 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/117163 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Axonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105040748711&origin=inward | |
| oaire.citation.issue | 1 | |
| oaire.citation.title | BMC Neurology | |
| oaire.citation.volume | 26 | |
| oairecerif.author.affiliation | Mahidol University | |
| oairecerif.author.affiliation | St. Jude Children's Research Hospital | |
| oairecerif.author.affiliation | Siriraj Hospital |
